Source: Eur Respir J, 51 (4) 1701836; 10.1183/13993003.01836-2017
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Joy Lee, Tunn Ren Tay, Naghmeh Radhakrishna, Fiona Hore-Lacy, Anna Mackay, Ryan Hoy, Eli Dabscheck, Robyn O'Hehir, Mark Hew. Nonadherence in the era of severe asthma biologics and thermoplasty. Eur Respir J, 51 (4) 1701836; 10.1183/13993003.01836-2017

Member's Comments

No comment yet.

Related content which might interest you: Thermoplasty for severe asthma Source: ERS Skills Course 2016 Year: 2016 Biologic therapies in paediatric severe asthma Source: ERS webinar 2020: Biologic therapies in paediatric severe asthma Year: 2020 Combination asthma medication and healthcare use in severe or difficult-to-treat asthma Source: Eur Respir J 2004; 24: Suppl. 48, 131s Year: 2004 Nonadherence with inhaled preventer therapy in severe asthmatic patients on long-term omalizumab Source: Eur Respir J, 52 (2) 1801025; 10.1183/13993003.01025-2018 Year: 2018 Cost effectiveness of bronchial thermoplasty for treatment of severe asthma patients in spain Source: International Congress 2017 – Does economisation of medicine transfer into benefits for patients? Year: 2017 Bronchial thermoplasty: a new therapeutic option for the treatment of severe, uncontrolled asthma in adults Source: Eur Respir Rev 2014; 23: 510-518 Year: 2014 Montelukast as add-on therapy in severe noninfectious COPD exacerbations Source: Eur Respir J 2003; 22: Suppl. 45, 241s Year: 2003 Bronchial thermoplasty benefits patients following withdrawal of LABA therapy Source: Annual Congress 2010 - New treatments for asthma and COPD Year: 2010 The effectiveness of anti-IL5 biologics is comparable in previous-smokers and never-smokers with severe asthma Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021 The use of omalizumab in the management of severe chronic paediatric asthma Source: Annual Congress 2008 - Drug therapy and assessment of control in childhood asthma Year: 2008 Anti-IgE therapy with omalizumab decreases exacerbations in patients with poorly controlled moderate-to-severe allergic asthma Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003 Real-life long-term omalizumab therapy in children with severe allergic asthma Source: Eur Respir J 2015; 46: 856-859 Year: 2015 Adherence to corticosteroids and clinical outcomes in mepolizumab therapy for severe asthma Source: Eur Respir J, 55 (5) 1902259; 10.1183/13993003.02259-2019 Year: 2020 Omalizumab: therapeutic approach to asthma and comorbidities Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Omalizumab, a novel therapy for severe allergic asthma Source: Eur Respir J 2001; 18: Suppl. 33, 37s Year: 2001 Pharmacological strategies for self-management of asthma exacerbations Source: Eur Respir J 2006; 28: 182-199 Year: 2006 Cost of asthma rescue/acute and allergy medications among asthmatic patients on controller therapy Source: Eur Respir J 2004; 24: Suppl. 48, 344s Year: 2004 Inhaled antibiotic therapy in patients with severe asthma Source: Virtual Congress 2021 – Advances in asthma treatment Year: 2021 Once-daily tiotropium respimat add-on to at least ICS maintenance therapy reduces exacerbation risk in patients with uncontrolled symptomatic asthma Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014